128 results
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
26 Nov 18
Current report (foreign)
4:20pm
from a recent phase 1/2 clinical trial to test the safety and efficacy of injections of RCT-01 on patients suffering from chronic achilles tendinosis … clinical trial to test the safety and certain biological outcomes of injections of RCS-01 in patients with aging and sun-damaged skin supports regulatory
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
31 Aug 21
Condensed Consolidated Interim Financial Statements
1:45pm
which are limited in efficacy;
belief that the data from a phase 1/2 clinical trial to test the safety and efficacy of injections of RCT-01 … of such a dose-finding trial;
belief that the data from the phase 1 clinical trial to test the safety and certain biological outcomes of injections
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
24 Sep 19
Current report (foreign)
1:49pm
trial was a randomized, double-blind, placebo-controlled, single-centre, phase I safety study of intradermal injections of RCS-01 in healthy subjects … . The primary endpoint was to assess the local safety profile by recording and evaluating adverse events reported at the treatment evaluation sites
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
30 Nov 23
Condensed Consolidated Interim Financial Statements
1:05pm
or corticosteroids, which are limited in efficacy;
belief that the data from a phase 1/2 clinical trial to test the safety and efficacy of injections … to a phase 2 trial and the design of such a dose-finding trial;
belief that the data from the phase 1 clinical trial to test the safety and certain
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
18 Aug 21
Current report (foreign)
12:20pm
clinical research study of its tendon regeneration cell therapy, RCT-01, in Japan under the Act for Safety of Regenerative Medicine (ASRM) that, upon … of establishing a complete safety profile at 6 months with no serious adverse events related to the study treatment or injection procedure and furthermore each
6-K
EX-99.2
ncv1bp7h u1y
24 Oct 23
Condensed Consolidated Interim Financial Statements
11:10am
6-K
EX-99.2
n79uqa2zx5smyrcft2
30 May 23
Condensed Consolidated Interim Financial Statements
5:40pm
6-K
EX-99.2
3zo4 26zv6w6vc
31 Jul 20
Condensed Consolidated Interim Financial Statements
9:14pm
6-K
EX-99.2
r72zd5b8r2s zhwpzn
30 May 18
Condensed Consolidated Interim Financial Statements
12:00am
6-K
EX-99.4
ujk3pza5s9zh7bm2zvn
7 Jul 22
RepliCel Provides Update on Private Placement
3:36pm
6-K
EX-99.2
w50gnys8q89jx
30 Nov 21
Condensed Consolidated Interim Financial Statements
1:50pm
6-K
EX-99.2
e5h98brmlcz2
1 Jun 21
Condensed Consolidated Interim Financial Statements
3:57pm
6-K
EX-99.2
8r34jww
6 Sep 22
Condensed Consolidated Interim Financial Statements
12:42pm
6-K
EX-99.2
xzxw7hm28jowlu 1i
15 Oct 20
Condensed Consolidated Interim Financial Statements
5:15pm
6-K
EX-99.2
ecs5xh
30 Nov 20
Condensed Consolidated Interim Financial Statements
5:19pm
6-K
EX-99.2
41973urmum
27 Nov 19
Condensed Consolidated Interim Financial Statements
5:09pm
6-K
EX-99.2
602qk6fxzfcdhw 743il
28 Aug 13
Current report (foreign)
12:00am
6-K
EX-99.2
ia0rb 9e3jp
30 May 19
Condensed Consolidated Interim Financial Statements
4:20pm
6-K
EX-99.2
ebw26n0vzw
3 Aug 20
Consolidated Financial Statements
12:00am
6-K
EX-99.2
97oe7ukhfv9yu7vm
23 Aug 19
Condensed Consolidated Interim Financial Statements
3:47pm